A NanoBiT-based high-throughput assay system for monitoring osteoclast fusion. (PubMed, Anal Biochem) - Sep 12, 2026 - "In addition, luciferase activity was inhibited by cyclosporin A in a dose-dependent manner and completely abolished by Dcstamp knockout, demonstrating its validity for chemical screening and for evaluating genes involved in osteoclast fusion. Using this platform, we screened approximately 2,300 known bioactive compounds and identified THZ-P1-2, a phosphatidylinositol-5-phosphate 4-kinase type 2 inhibitor, and Brequinar, a dihydroorotate dehydrogenase inhibitor, as novel modulators of osteoclast fusion. Compared with fluorescence-based assays, this luminescence-based system minimizes false-positive signals caused by cellular or compound autofluorescence and provides superior sensitivity and quantifiability. Furthermore, the assay is rapid, simple, and highly compatible with high-throughput screening, making it a useful platform for studying osteoclast fusion and for screening compounds that modulate this process."
Journal • IL4
|
|
Keiichiro Yogo; Momoka Nakatani; Muneaki Yoshino; Norihiro Ishida-Kitagawa; Sumire Hanahira; Takuya Ogawa; Wataru Fujii
|